
I help our clients design and implement compensation arrangements for executives and employees.
Experience
ACELYRIN Announces Pricing of Upsized Initial Public Offering
May 15, 2023
Cooley advised Acelyrin, INC., a late-stage biopharmaceutical company, in its $621 million initial public offering, the second-largest biotechnology IPO and largest clinical-stage biotechnology IPO ever.
Related contacts
Related Practices & Industries
Structure Therapeutics – $185.3 Million IPO
February 9, 2023
San Francisco – February 9, 2023 – Cooley advised Structure Therapeutics, a clinical-stage global biopharmaceutical company, on its $185.3 million initial public offering, including the full exercise of the underwriters’ option to purchase additional American depositary shares. Lawyers Charlie Kim, Patrick Loofbourrow, Andrew Harline and Su Lian Lu led the Cooley team.
The offering marks the first sizable US life sciences IPO this year. Structure Therapeutics will use the proceeds to develop new oral therapies for the treatment of various diseases, including those impacting the metabolic, cardiovascular and pulmonary systems. Its lead product candidate targets Type 2 diabetes and obesity.
Structure Therapeutics aims to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages structure-based drug discovery and computational chemistry expertise, enabling it to build a pipeline of product candidates. The company currently focuses on G-protein-coupled receptors as a therapeutic target class.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.
Related contacts
Related Practices & Industries
Horizon Therapeutics to Be Acquired by Amgen for Approximately $28 Billion
December 20, 2022
A Cooley team advised Horizon Therapeutics, a specialty biopharmaceutical company, on its agreement to be acquired by Amgen. The approximately $28 billion merger would represent the third-largest all-cash transaction in the pharmaceutical sector in history and the biggest healthcare deal of 2022.
Related contacts
Related Practices & Industries
NeoPhotonics Agrees to Sell to Lumentum for $918 Million
November 8, 2021
Cooley advised NeoPhotonics, a developer and manufacturer of optoelectronic solutions, on its agreement to sell to Lumentum for $918 million. Lawyers Steve Tonsfeldt, Ian Nussbaum, John Sellers and Rishab Kumar led the Cooley team advising NeoPhotonics.
Related contacts
Related Practices & Industries
Flexion Therapeutics Agrees to Sell to Pacira BioSciences
October 13, 2021
Cooley advised Flexion Therapeutics, a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of patients with musculoskeletal conditions, on its agreement to sell to Pacira BioSciences. Lawyers Miguel Vega, Kevin Cooper, Sean Clayton and Matthew Silverman led the Cooley team advising Flexion.